Total Payments
$119,492
2024 Payments
$12,336
Companies
23
Transactions
512
Medicare Patients
4,529
Medicare Billing
$1.3M
Payment Breakdown by Category
Other$95,919 (80.3%)
Food & Beverage$12,516 (10.5%)
Consulting$6,000 (5.0%)
Travel$5,004 (4.2%)
Education$51.94 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $67,424 | 53 | 56.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $26,495 | 13 | 22.2% |
| Food and Beverage | $12,516 | 398 | 10.5% |
| Consulting Fee | $6,000 | 4 | 5.0% |
| Travel and Lodging | $5,004 | 40 | 4.2% |
| Honoraria | $2,000 | 2 | 1.7% |
| Education | $51.94 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $29,929 | 196 | $0 (2021) |
| Shionogi Inc | $23,174 | 33 | $0 (2024) |
| Cumberland Pharmaceuticals, Inc. | $17,538 | 41 | $0 (2023) |
| ABBVIE INC. | $14,093 | 102 | $0 (2024) |
| Theravance Biopharma, Inc. | $13,456 | 40 | $0 (2018) |
| Melinta Therapeutics, LLC | $12,892 | 54 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $3,235 | 7 | $0 (2021) |
| The Medicines Company | $2,219 | 7 | $0 (2017) |
| CIPLA USA INC. | $1,830 | 4 | $0 (2021) |
| BSN Medical Inc | $174.14 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,336 | 42 | Shionogi Inc ($5,289) |
| 2023 | $24,911 | 72 | Shionogi Inc ($10,810) |
| 2022 | $13,306 | 53 | Shionogi Inc ($7,074) |
| 2021 | $10,436 | 45 | Cumberland Pharmaceuticals, Inc. ($6,394) |
| 2020 | $4,061 | 46 | Allergan, Inc. ($3,772) |
| 2019 | $10,095 | 57 | Allergan Inc. ($5,713) |
| 2018 | $22,615 | 105 | Allergan Inc. ($13,226) |
| 2017 | $21,732 | 92 | Theravance Biopharma Inc. ($9,213) |
All Payment Transactions
512 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2024 | Kerecis Limited | Kerecis Omega3 SurgiClose (Device), Kerecis Omega3 Marigen, Kerecis Omega3 Marigen | Food and Beverage | Cash or cash equivalent | $89.79 | General |
| Category: Wound Care | ||||||
| 11/12/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Rezzayo | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: ANTIBIOTICS | ||||||
| 10/29/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Food and Beverage | In-kind items and services | $11.77 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/18/2024 | ABBVIE INC. | DALVANCE (Drug), AVYCAZ, TEFLARO | Food and Beverage | In-kind items and services | $34.88 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/09/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $37.30 | General |
| Category: Respiratory | ||||||
| 10/07/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Rezzayo | Food and Beverage | In-kind items and services | $27.96 | General |
| Category: ANTIBIOTICS | ||||||
| 10/01/2024 | ABBVIE INC. | DALVANCE (Drug), AVYCAZ, TEFLARO | Food and Beverage | In-kind items and services | $6.70 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/24/2024 | Shionogi Inc | Fetroja (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,370.00 | General |
| Category: Infections and Infectious Diseases | ||||||
| 09/24/2024 | ABBVIE INC. | DALVANCE (Drug), AVYCAZ, TEFLARO | Food and Beverage | In-kind items and services | $12.05 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/19/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $42.97 | General |
| Category: ANTIFUNGALS | ||||||
| 09/18/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $30.20 | General |
| Category: Infections and Infectious Diseases | ||||||
| 09/12/2024 | ABBVIE INC. | DALVANCE (Drug), AVYCAZ, TEFLARO | Food and Beverage | In-kind items and services | $20.72 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/27/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ, DALVANCE | Food and Beverage | In-kind items and services | $6.97 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/14/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $27.76 | General |
| Category: ANTIFUNGALS | ||||||
| 08/13/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/08/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: ANTIBIOTICS | ||||||
| 08/08/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug) | Food and Beverage | In-kind items and services | $95.95 | General |
| Category: ANTIBIOTICS | ||||||
| 07/23/2024 | ABBVIE INC. | DALVANCE (Drug), AVYCAZ, TEFLARO | Food and Beverage | In-kind items and services | $8.86 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/16/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Food and Beverage | In-kind items and services | $205.18 | General |
| Category: ANTIFUNGALS | ||||||
| 07/09/2024 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,250.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/02/2024 | Kerecis Limited | Kerecis Omega3 SurgiClose (Device), Kerecis Omega3 Marigen, Kerecis Omega3 Marigen | Food and Beverage | Cash or cash equivalent | $6.52 | General |
| Category: Wound Care | ||||||
| 06/25/2024 | Shionogi Inc | Fetroja (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,370.00 | General |
| Category: Infections and Infectious Diseases | ||||||
| 06/25/2024 | ABBVIE INC. | DALVANCE (Drug), AVYCAZ, TEFLARO | Food and Beverage | In-kind items and services | $12.10 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/18/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $17.73 | General |
| Category: ANTIBIOTIC | ||||||
| 06/13/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $124.28 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 863 | 3,855 | $1.0M | $274,151 |
| 2022 | 11 | 1,114 | 5,293 | $1.4M | $347,261 |
| 2021 | 11 | 1,229 | 4,842 | $1.3M | $338,758 |
| 2020 | 7 | 1,323 | 5,746 | $1.5M | $377,784 |
Total Patients
4,529
Total Services
19,736
Medicare Billing
$1.3M
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 461 | 3,243 | $719,946 | $202,290 | 28.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 309 | 379 | $236,117 | $51,908 | 22.0% |
| 99183 | Management of oxygen chamber therapy | Facility | 2023 | 14 | 106 | $36,040 | $8,831 | 24.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 50 | 87 | $27,927 | $8,176 | 29.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 17 | 17 | $7,140 | $1,749 | 24.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 12 | 23 | $5,198 | $1,198 | 23.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 560 | 4,282 | $950,581 | $245,093 | 25.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 345 | 385 | $239,855 | $61,096 | 25.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 36 | 192 | $43,392 | $10,393 | 24.0% |
| 99183 | Management of oxygen chamber therapy | Facility | 2022 | 20 | 114 | $38,760 | $9,985 | 25.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 52 | 116 | $37,236 | $9,267 | 24.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 25 | 25 | $10,500 | $2,742 | 26.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 20 | 83 | $11,326 | $2,452 | 21.7% |
| 11042 | Removal of skin and tissue, 20.0 sq cm or less | Facility | 2022 | 12 | 39 | $9,750 | $1,928 | 19.8% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Facility | 2022 | 16 | 29 | $6,177 | $1,615 | 26.2% |
| 99306 | Initial nursing facility visit per day, typically 45 minutes | Facility | 2022 | 12 | 12 | $6,156 | $1,598 | 26.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 16 | 16 | $5,344 | $1,092 | 20.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 637 | 3,949 | $876,678 | $231,545 | 26.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 369 | 427 | $266,021 | $69,478 | 26.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 81 | 154 | $49,434 | $12,933 | 26.2% |
| 99183 | Management and supervision of oxygen chamber therapy per session | Office | 2021 | 12 | 122 | $41,480 | $11,075 | 26.7% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Facility | 2021 | 32 | 61 | $12,993 | $3,435 | 26.4% |
| 99306 | Initial nursing facility visit, typically 45 minutes per day | Facility | 2021 | 20 | 20 | $10,260 | $2,711 | 26.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 24 | 24 | $10,080 | $2,671 | 26.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 17 | 34 | $7,684 | $1,890 | 24.6% |
About Dr. Dhiresh Joshi, M.D
Dr. Dhiresh Joshi, M.D is a Infectious Disease healthcare provider based in Las Vegas, Nevada. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1225194293.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dhiresh Joshi, M.D has received a total of $119,492 in payments from pharmaceutical and medical device companies, with $12,336 received in 2024. These payments were reported across 512 transactions from 23 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($67,424).
As a Medicare-enrolled provider, Joshi has provided services to 4,529 Medicare beneficiaries, totaling 19,736 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Las Vegas, NV
- Active Since 12/27/2006
- Last Updated 09/26/2022
- Taxonomy Code 207RI0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1225194293
Products in Payments
- VIBATIV (Drug) $28,777
- DALVANCE (Drug) $21,566
- AVYCAZ (Drug) $19,516
- Fetroja (Drug) $15,593
- Vabomere (Drug) $7,597
- Kimyrsa (Drug) $4,742
- ZERBAXA (Drug) $3,174
- TEFLARO (Drug) $2,940
- VABOMERE (Drug) $2,194
- ZEMDRI (PLAZOMICIN) (Drug) $1,830
- Rezzayo (Drug) $275.91
- Orbactiv (Drug) $231.62
- XERAVA (Drug) $217.75
- Vibativ (Drug) $184.29
- JOBST FORMEN AMBITION (Device) $174.14
- IGT_D Peripheral (Device) $111.79
- Kerecis Omega3 SurgiClose (Device) $104.12
- Arikayce (Drug) $77.98
- NUZYRA (Drug) $62.48
- Omnilink Elite vascular stent system (Device) $59.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Las Vegas
Dr. Alireza Farabi, Md, MD
Infectious Disease — Payments: $641,161
Infectious Disease $641,161
Dr. Dhaval Shah, M.d, M.D
Infectious Disease — Payments: $40,851
Infectious Disease $40,851
Dr. Alka Rebentish, Md, MD
Infectious Disease — Payments: $25,493
Infectious Disease $25,493
Ronald Shockley, M.d, M.D
Infectious Disease — Payments: $15,593
Infectious Disease $15,593
Li-Chien Chen, D.o, D.O
Infectious Disease — Payments: $8,545
Infectious Disease $8,545
Naima Zaheer, Md, MD
Infectious Disease — Payments: $6,914
Infectious Disease $6,914